Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;57(2):291-298.
doi: 10.1134/S0026893323020152. Epub 2023 Apr 26.

Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2

L A Oleinik  1 , P G Madonov  1 , M B Pykhtina  1
Affiliations

Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2

L A Oleinik et al. Mol Biol. 2023.

Abstract

This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020‒2022. The results of our own studies of pharmacological substances based on recombinant IFN-λ1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-λ as an effective therapeutic agent against SARS-CoV-2.

Keywords: PEG-interferon-λ1; SARS-CoV-2; antiviral activity; recombinant human interferon-λ1.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest. This article does not contain any studies involving animals or human participants performed by any of the authors.

Figures

Fig. 1.
Fig. 1.
The effect of types I, II, and III interferons on infected SARS-CoV-2 Vero E6 cells. (a) The percentage of infected Vero E6 cells estimated as the ratio of cells positive for the viral nucleoprotein (NP) to the total number of cells (the data are shown as mean value ± standard deviation, n = 3). (b) Analysis of virus titers expressed as TCID50 in Vero E6 cell supernatants (data are shown as mean ± SEM, n = 3) [17, Creative Commons Attribution License 4.0 (CC BY)].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Schneider W.M., Chevillotte M.D., Rice C.M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 2014;32:513–545. doi: 10.1146/annurev-immunol-032713-120231. - DOI - PMC - PubMed
    1. Totura A.L., Baric R.S. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr. Opin. Virol. 2012;2:264–275. doi: 10.1016/j.coviro.2012.04.004. - DOI - PMC - PubMed
    1. Andreakos E., Salagianni M., Galani I.E., Koltsida O. Interferon-lambdas: front-line guardians of immunity and homeostasis in the respiratory tract. Front. Immunol. 2017;8:1232. doi: 10.3389/fimmu.2017.01232. - DOI - PMC - PubMed
    1. Dellgren C., Gad H.H., Hamming O.J., Melchjorsen J., Hartmann R. Human interferon-λ3 is a potent member of the type III interferon family. Genes Immun. 2009;10:125–131. doi: 10.1038/gene.2008.87. - DOI - PubMed
    1. Galani I.E., Triantafyllia V., Eleminiadou E.E., Koltsida O., Stavropoulos A., Manioudaki M., Thanos D., Doyle S.E., Kotenko S.V., Thanopoulou K., Andreakos E. Interferon-λ mediates nonredundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity. 2017;46:875–890. e6. doi: 10.1016/j.immuni.2017.04.025. - DOI - PubMed

LinkOut - more resources